Printer Friendly

NOVO NORDISK'S NORTH CAROLINA FACILITY TO BECOME LARGEST ENZYME FACTORY IN THE AMERICAS

 NOVO NORDISK'S NORTH CAROLINA FACILITY TO BECOME
 LARGEST ENZYME FACTORY IN THE AMERICAS
 FRANKLINTON, N.C., April 30 /PRNewswire/ -- Denmark-based Novo Nordisk A/S (NYSE: NVO) today announced plans to expand substantially its enzyme manufacturing facility in Franklinton. The capital investment of approximately $100 million will make the U.S. operation the largest multi-purpose enzyme plant in the Americas and, when operational in 1994, will create approximately 100 new full-time jobs.
 North Carolina Gov. James Martin and His Excellency Peter Dyvig, Denmark's ambassador to the United States, joined Novo Nordisk President and Chief Executive Officer Mads Ovlisen, and Steen Riisgaard, executive vice president of Novo Nordisk and president of its Bioindustrial Group, at today's ground-breaking ceremonies.
 "American industry has shown a keen interest in using enzymes to create better products and to create more economical and more environmentally friendly processes," said Ovlisen. "This investment reflects that demand and our commitment to meet it."
 Although some product may be exported, the facility expansion is designed to serve the needs of U.S. customers, especially detergent manufacturers. The expanded plant will include a granulation tower for coating the enzymes used in detergents.
 "The expanded plant will generate significant economies of scale as the use of enzymes spreads among more companies in more industries," Riisgaard explained. "Those economies are essential to affordable prices for our customers and to the savings for funding research and development of new enzymes for new uses."
 Novo Nordisk is the world's largest producer of industrial enzymes and, worldwide, its Bioindustrial Group markets more than 40 different enzymes for use by the detergent, beverage, textiles, starch, baking, fruit juice, paper and other industries.
 In addition, Novo Nordisk is the world leader in the development and manufacture of insulin and diabetes-care products. It also manufactures and markets a variety of other pharmaceutical and bioindustrial products. Headquartered in Denmark, Novo Nordisk employs 10,000 people in over 40 countries and markets its products in more than 130 countries.
 -0- 4/30/92
 /CONTACT: Margaret Jo Ringsted of Novo Nordisk of North America, 212-867-0123, or Leonard Ellis of Fleishman-Hillard, Inc., 212-265-9150, for Novo Nordisk/
 (NVO) CO: Novo Nordisk A/S ST: North Carolina IN: MTC SU:


AH-TQ -- NY096 -- 5123 04/30/92 16:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:373
Previous Article:MARTIN MARIETTA, LOCKHEED CEOs URGE BAN ON FOREIGN GOVERNMENT OWNERSHIP, CONTROL OF U.S. DEFENSE SUPPLIERS
Next Article:DELPHI FINANCIAL GROUP REPORTS FIRST QUARTER EARNINGS


Related Articles
NOVO NORDISK A/S NAMES HENRIK AAGAARD PRESIDENT OF NOVO NORDISK OF NORTH AMERICA INC. IN NEW YORK
LARGEST ENZYME PLANT IN AMERICAS INAUGURATED BY NOVO NORDISK
NOVO NORDISK BIOINDUSTRIAL GROUP WILL RELOCATE NORTH AMERICAN SALES AND MARKETING DIVISION
NOVO NORDISK EXPANDS EXECUTIVE BOARD
NOVO NORDISK OBTAINS LAND USE RIGHTSFOR PRODUCTION FACILITY IN CHINA
NOVO NORDISK TO BUILD PHARMACEUTICAL PLANT IN JAPAN
REVOLUTIONARY FOOD PROCESSING ENZYME INTRODUCED COMMERCIALLY BY NOVO NORDISK
Novo Nordisk Opens Insulin Manufacturing Facility In N.C.
Novo Nordisk Acquires Enzyme Patents and Know-How From Showa Denko
Novo Nordisk BioChem North America Contributes Funds to Support Expansion of Vance-Granville Community College.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters